Biophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19 - Biophytis (NASDAQ:BPTS)

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(PARIS:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics

Related Keywords

United States ,Paris ,France General ,France ,Cambridge ,Cambridgeshire ,United Kingdom ,Massachusetts ,Veillet ,Rhôalpes ,Antoine Denry ,Agathe Boggio ,Nizar Berrada ,Nicolas Fellmann ,Exchange Commission ,Drug Administration ,European Medicine Agency ,Emergency Use Authorization ,Chief Executive Officer ,Acute Respiratory Distress Syndrome ,Emergency Use Application ,Duchenne Muscular Dystrophy ,Euronext Growth ,American Depositary Shares ,Nasdaq Capital Market ,